Recently, Calico Life Sciences announced that their drug candidate Fosigotifator has been selected for the FDA's START Pilot Program. Fosigotifator aims to treat Amyotrophic Lateral Sclerosis (ALS) disease, a rare and fatal neurological condition.

Fosigotifator targets a specific pathway implicated in the progression of ALS disease, aiming to stabilize or improve neurological function. The selection of this candidate for the START Pilot Program highlights its potential as a groundbreaking treatment for this devastating disease.

Nevertheless, the development of analogs of this molecule continues to be carried out to study its potential to improve its efficacy and safety.

To expand further research, we created a set of analogs of the bridge bicyclo[2.2.2]octane.

Interested or have any questions? Contact us at info@chem-space.com.